![](/wp-content/uploads/2020/08/Lannett-Earnings.png)
$599
Lannett CY Q2 ‘21 (FY Q4 ’21) Earnings Update
Lannett hosted its CY Q2 ’21 (FY Q4 ’21) earnings call in which it provided brief updates to its biosimilar glargine U100 and biosimilar aspart development programs. Of note, Lannett now anticipates filing the bs-glargine BLA in H1 ’23 (previously “later in 2022”) with a US launch planned for H1 ’24 (previously 2023). Below, FENIX provides highlights and insights from the call.